Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs

(2020) Michael S. Seaman et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

(2020) Julia Niessl et al.   NATURE MEDICINE

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

(2019) Christine A. Bricault et al.   Cell Host & Microbe

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Trevor A Crowell et al.   Lancet HIV

Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection

(2018) Hongshuo Song et al.   Nature Communications

Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

(2018) Yehuda Z. Cohen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

(2018) Yotam Bar-On et al.   NATURE MEDICINE

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

(2018) Erica N. Borducchi et al.   NATURE

Early antibody therapy can induce long-lasting immunity to SHIV

(2017) Yoshiaki Nishimura et al.   NATURE

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

(2017) Boris Julg et al.   Science Translational Medicine

Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G

(2016) Guillaume B.E. Stewart-Jones et al.   CELL

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans

(2016) Devin Sok et al.   IMMUNITY

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

(2016) Erica N. Borducchi et al.   NATURE

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

(2016) Johannes F. Scheid et al.   NATURE

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

(2016) Katharine J. Bar et al.   NEW ENGLAND JOURNAL OF MEDICINE

W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis

(2016) Jana Trifinopoulos et al.   NUCLEIC ACIDS RESEARCH

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

(2016) Kshitij Wagh et al.   PLoS Pathogens

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

CATNAP: a tool to compile, analyze and tally neutralizing antibody panels

(2015) Hyejin Yoon et al.   NUCLEIC ACIDS RESEARCH

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV

(2014) D. Sok et al.   Science Translational Medicine

Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248

(2013) Adriana Andrade et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life

(2013) N L Yates et al.   Mucosal Immunology

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

(2013) Dan H. Barouch et al.   NATURE

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans

(2013) Jean-Philippe Julien et al.   PLoS Pathogens

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

A quantitative basis for antiretroviral therapy for HIV-1 infection

(2012) Benjamin L Jilek et al.   NATURE MEDICINE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

(2012) B. Moldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

(2012) H. Mouquet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

(2010) L. Rong et al.   Science Translational Medicine

Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies

(2009) M. S. Seaman et al.   JOURNAL OF VIROLOGY

Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

(2008) G. D. Tomaras et al.   JOURNAL OF VIROLOGY

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA